CY1121862T1 - Αντισωματα anti-phf-tau και χρησεις αυτων - Google Patents

Αντισωματα anti-phf-tau και χρησεις αυτων

Info

Publication number
CY1121862T1
CY1121862T1 CY20191100834T CY191100834T CY1121862T1 CY 1121862 T1 CY1121862 T1 CY 1121862T1 CY 20191100834 T CY20191100834 T CY 20191100834T CY 191100834 T CY191100834 T CY 191100834T CY 1121862 T1 CY1121862 T1 CY 1121862T1
Authority
CY
Cyprus
Prior art keywords
phf
tau antibodies
tau
antibodies
making
Prior art date
Application number
CY20191100834T
Other languages
English (en)
Inventor
Christopher ALDERFER
Dariusz Janecki
Xuesong Liu
Melissa MURDOCK
Sheng-Jiun Wu
Marc Mercken
Marc Vandermeeren
Thomas Malia
Original Assignee
Janssen Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech, Inc. filed Critical Janssen Biotech, Inc.
Publication of CY1121862T1 publication Critical patent/CY1121862T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Η παρούσα εφεύρεση σχετίζεται με αντισώματα αντι-PHF-tau και με μεθόδους παρασκευής και χρήσης αυτών.
CY20191100834T 2011-12-20 2019-08-06 Αντισωματα anti-phf-tau και χρησεις αυτων CY1121862T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161577817P 2011-12-20 2011-12-20
PCT/US2012/070486 WO2013096380A2 (en) 2011-12-20 2012-12-19 Anti-phf-tau antibodies and their uses

Publications (1)

Publication Number Publication Date
CY1121862T1 true CY1121862T1 (el) 2020-07-31

Family

ID=48669693

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100834T CY1121862T1 (el) 2011-12-20 2019-08-06 Αντισωματα anti-phf-tau και χρησεις αυτων

Country Status (34)

Country Link
US (4) US9371376B2 (el)
EP (2) EP3578567A1 (el)
JP (4) JP6306513B2 (el)
KR (1) KR101991681B1 (el)
CN (2) CN104024274B (el)
AU (2) AU2012359039B2 (el)
BR (1) BR112014015323B1 (el)
CA (2) CA2859665A1 (el)
CO (1) CO6980627A2 (el)
CY (1) CY1121862T1 (el)
DK (1) DK2794654T3 (el)
EA (1) EA027975B1 (el)
EC (1) ECSP14005975A (el)
ES (1) ES2738007T3 (el)
GT (1) GT201400127A (el)
HK (2) HK1203520A1 (el)
HR (1) HRP20191342T1 (el)
HU (1) HUE045656T2 (el)
IL (3) IL233051B (el)
LT (1) LT2794654T (el)
MX (1) MX350311B (el)
MY (2) MY178142A (el)
NI (1) NI201400061A (el)
NZ (1) NZ626269A (el)
PH (1) PH12014501427B1 (el)
PL (1) PL2794654T3 (el)
PT (1) PT2794654T (el)
RS (1) RS59024B1 (el)
SG (1) SG11201403106SA (el)
SI (1) SI2794654T1 (el)
TR (1) TR201910720T4 (el)
UA (1) UA114902C2 (el)
WO (1) WO2013096380A2 (el)
ZA (1) ZA201405317B (el)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6306513B2 (ja) * 2011-12-20 2018-04-04 ヤンセン バイオテツク，インコーポレーテツド 抗ＰＨＦ−ｔａｕ抗体及びその使用
CN104781278B (zh) 2012-07-03 2018-06-12 华盛顿大学 针对tau的抗体
MX359817B (es) 2012-08-16 2018-10-11 Ipierian Inc Anticuerpos que se enlazan a tau.
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
NZ630610A (en) 2014-02-14 2019-05-31 Ipierian Inc Tau peptides, anti-tau antibodies, and methods of use thereof
ZA201608812B (en) * 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
CN107074935B (zh) * 2014-06-26 2021-08-03 扬森疫苗与预防公司 特异性结合微管相关蛋白tau的抗体和抗原结合片段
TWI664190B (zh) 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
WO2016112078A2 (en) * 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
AR103713A1 (es) 2015-02-26 2017-05-31 Lilly Co Eli Anticuerpos contra tau y sus usos
CN107849124B (zh) 2015-06-05 2021-09-24 基因泰克公司 抗tau抗体及使用方法
MA41669A1 (fr) * 2015-07-06 2018-05-31 Ucb Biopharma Sprl Anticorps se liant a tau
US10287343B2 (en) * 2015-07-06 2019-05-14 Ucb Biopharma Sprl Tau-binding antibodies
WO2017189963A1 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2018031361A2 (en) 2016-08-09 2018-02-15 Eli Lilly And Company Combination therapy
CR20230163A (es) 2016-12-07 2023-07-06 Genentech Inc ANTICUERPOS ANTITAU Y MÉTODOS DE USO (Divisional 2019-0271)
AU2017373884A1 (en) 2016-12-07 2019-05-30 Ac Immune Sa Anti-tau antibodies and methods of their use
EP3583123A1 (en) 2017-02-17 2019-12-25 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
JOP20180021A1 (ar) * 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
TWI750419B (zh) 2017-10-16 2021-12-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
CN112105639A (zh) * 2018-03-05 2020-12-18 詹森药业有限公司 抗PHF-tau抗体及其用途
WO2019171258A1 (en) 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Assays to detect neurodegeneration
RU2020135052A (ru) * 2018-03-28 2022-04-29 Аксон Ньюросайенс Се Способы выявления и лечения болезни альцгеймера на основе антител
JP2021530552A (ja) 2018-07-31 2021-11-11 イーライ リリー アンド カンパニー 併用療法
BR112022020753A2 (pt) 2020-04-15 2022-12-20 Voyager Therapeutics Inc Compostos de ligação a tau
AR122721A1 (es) 2020-06-25 2022-09-28 Merck Sharp & Dohme Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413
AU2021403010A1 (en) 2020-12-16 2023-07-13 Voyager Therapeutics, Inc. Tau binding compounds
IL307170A (en) * 2021-03-26 2023-11-01 Janssen Biotech Inc Anti-tau antibodies and their uses
AU2022246275A1 (en) * 2021-03-26 2023-11-09 Janssen Biotech, Inc. Humanized antibodies against paired helical filament tau and uses thereof
WO2023250388A1 (en) 2022-06-22 2023-12-28 Voyager Therapeutics, Inc. Tau binding compounds
WO2024059739A1 (en) 2022-09-15 2024-03-21 Voyager Therapeutics, Inc. Tau binding compounds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3909084B2 (ja) * 1991-10-25 2007-04-25 エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム 微小管結合タンパク質タウに対するモノクローナル抗体
EP0737208B1 (en) * 1993-12-21 2006-08-02 Innogenetics N.V. Monoclonal antibodies specific for phf-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications
AU710952B2 (en) * 1994-07-29 1999-09-30 Innogenetics N.V. Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
EP2221315A1 (en) 2003-12-04 2010-08-25 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US20070280935A1 (en) * 2006-04-07 2007-12-06 Bernd Bohrmann Antibody that recognizes phosphorylated peptides
CA2659820A1 (en) * 2006-08-04 2008-02-14 Novartis Ag Ephb3-specific antibody and uses thereof
JP2010235447A (ja) * 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk 炎症性サイトカインの抑制剤
EP2347038A4 (en) 2008-10-14 2013-06-12 Janssen Biotech Inc METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES
US9968574B2 (en) * 2009-05-15 2018-05-15 The University Of Kentucky Research Foundation Treatment of MCI and Alzheimer's disease
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CA3120504A1 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
US8912355B2 (en) * 2009-09-29 2014-12-16 University Of Ottawa Heart Institute Linoleic phospholipids and uses thereof for inhibiting inflammatory and neurodegenerative processes
DK2488867T3 (da) 2009-10-14 2020-11-09 Janssen Biotech Inc Fremgangsmåder til affinitetsmodning af antistoffer
TW201216985A (en) 2010-10-07 2012-05-01 Ac Immune Sa Pharmaceutical composition
JP2014503178A (ja) 2010-10-11 2014-02-13 バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー ヒト抗タウ抗体
JP6306513B2 (ja) * 2011-12-20 2018-04-04 ヤンセン バイオテツク，インコーポレーテツド 抗ＰＨＦ−ｔａｕ抗体及びその使用

Also Published As

Publication number Publication date
HRP20191342T1 (hr) 2019-11-01
TR201910720T4 (tr) 2019-08-21
AU2017264975B2 (en) 2019-09-12
PH12014501427A1 (en) 2014-09-22
NI201400061A (es) 2016-12-02
US20150307600A1 (en) 2015-10-29
CO6980627A2 (es) 2014-06-27
AU2012359039B2 (en) 2017-08-24
JP2015500879A (ja) 2015-01-08
SI2794654T1 (sl) 2019-08-30
CN107226863B (zh) 2021-06-01
MY186066A (en) 2021-06-18
PH12014501427B1 (en) 2014-09-22
US20170355758A1 (en) 2017-12-14
CA3234629A1 (en) 2013-06-27
EA027975B1 (ru) 2017-09-29
US20160304593A1 (en) 2016-10-20
CN107226863A (zh) 2017-10-03
EP2794654A4 (en) 2015-09-30
NZ720141A (en) 2017-09-29
JP6987809B2 (ja) 2022-01-05
ES2738007T3 (es) 2020-01-17
CA2859665A1 (en) 2013-06-27
EP3578567A1 (en) 2019-12-11
JP2018078897A (ja) 2018-05-24
US10000559B2 (en) 2018-06-19
JP6695317B2 (ja) 2020-05-20
JP6306513B2 (ja) 2018-04-04
IL263021B (en) 2021-03-25
JP2019176866A (ja) 2019-10-17
HUE045656T2 (hu) 2020-01-28
IL263021A (en) 2018-12-31
BR112014015323A2 (pt) 2020-10-27
ECSP14005975A (es) 2015-07-31
AU2017264975A1 (en) 2017-12-21
EP2794654B1 (en) 2019-05-22
ZA201405317B (en) 2016-05-25
EA201491224A1 (ru) 2014-11-28
IL281250A (en) 2021-04-29
GT201400127A (es) 2015-03-23
SG11201403106SA (en) 2014-12-30
WO2013096380A3 (en) 2013-08-22
JP6987904B2 (ja) 2022-01-05
CN104024274B (zh) 2017-07-18
NZ626269A (en) 2016-06-24
BR112014015323B1 (pt) 2022-09-27
EP2794654A2 (en) 2014-10-29
WO2013096380A2 (en) 2013-06-27
CN104024274A (zh) 2014-09-03
US9371376B2 (en) 2016-06-21
PL2794654T3 (pl) 2019-11-29
JP2020105179A (ja) 2020-07-09
IL233051B (en) 2019-02-28
PT2794654T (pt) 2019-09-10
MY178142A (en) 2020-10-05
UA114902C2 (uk) 2017-08-28
HK1244490A1 (zh) 2018-08-10
LT2794654T (lt) 2019-11-11
DK2794654T3 (da) 2019-08-05
IL233051A0 (en) 2014-07-31
MX350311B (es) 2017-09-01
MX2014007476A (es) 2014-07-28
RS59024B1 (sr) 2019-08-30
KR101991681B1 (ko) 2019-06-21
US10196440B2 (en) 2019-02-05
KR20140107493A (ko) 2014-09-04
US9745371B2 (en) 2017-08-29
AU2012359039A1 (en) 2014-07-03
US20180305445A1 (en) 2018-10-25
HK1203520A1 (en) 2015-10-30

Similar Documents

Publication Publication Date Title
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
CY1123958T1 (el) Μεθοδος παρασκευης παραγωγων και ενδιαμεσων καρβαμοϋλπυριδονης
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
CY1120646T1 (el) Προγονικα κυτταρα μεσοδερμικης προελευσης
CR20150618A (es) Anticuerpos receptores de antitransferina y métodos de uso
CY1119055T1 (el) Αντισωματα που προσδενονται στην il-17a και στην il-17f
CY1118885T1 (el) Συνθετικες πεπτιδογλυκανες που δεσμευουν υαλουρονικο οξυ, παρασκευη, και μεθοδοι χρησης
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
MX2022000026A (es) Anticuerpos para tau.
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
CR20150046A (es) Anticuerpos anti-cd79b e inmunoconjugados
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
UY34206A (es) Anticuerpo monoclonal de interleucina-31
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
EA201391540A1 (ru) Агонисты fgfr1 и способы их применения
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
UY34343A (es) Proteinas de unión al antígeno cd27l
UA109931C2 (xx) Піримідинциклогексильні модулятори глюкокортикоїдних рецепторів
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
CY1121067T1 (el) Εμβολιο πεπτιδιου pcsk9
MX2014014381A (es) Anticuerpos de anti-teofilina y metodos de uso.